Cancer Products

The cancer market is growing at a faster rate than any other pharmaceutical market due to an ageing population in developed countries and more effective therapies being introduced. It is a specialist area with a small number of highly influential opinion leaders defining treatment guidelines. As such it is an ideal market for Protherics to develop and sell niche cancer products to capture the full commercial value of these products.

We have four products in development which aim to improve outcomes in the treatment of cancer. Our lead programme is Voraxaze™ (glucarpidase), an intervention treatment when methotrexate blood levels remain dangerously elevated following high dose therapy for the treatment of cancer.

For more information on our cancer products please click on the product name.

Products

Voraxaze™ is currently available on a named patient basis. Please see below. 

Research and Development

TECHNOLOGY USE STATUS PARTNER MARKET
Voraxaze™
Recombinant enzyme Treatment of patients experiencing or at risk of methotrexate toxicity due to delayed elimination

Pre-approval for intervention use

Available on named patient basis in EU and RoW. Supplied by AAIPharma under a Treatment Protocol in US

Protherics in-house sales and marketing together with local partners Global market potential of up to ~$50m for intervention use; ~$100-200m including planned use
OncoGel™
Injectable sustained-released paclitaxel formulation Oesophageal cancer

Primary brain cancer

A phase 2b study in the treatment of oesophageal cancer has been initiated and headline results are expected in 2010.

Phase 1/2 study in brain cancer is ongoing

 Diatos S.A. for markets outside of North America, Korea and Mexico US market potential of up to ~$300m
Prolarix™
Prodrug based selective chemotherapy Primary liver cancer Cancer Research UK (CRUK) phase 1 study ongoing in UK. Phase 2 study planned for H1 2008 Partner sought for Asia Global market potential of ~$1bn
Acadra™ (acadesine)
Nucleoside analogue B-cell chronic lymphocytic leukaemia (B-CLL) Clinical proof-of-concept phase 1/2 study initiated and preliminary results expected mid 2008 Codevelopment with Advanced In Vitro Cell Technologies (Advancell). Protherics has exclusive global commercialization rights US and EU market potential of up to ~$250m

 * Based on Protherics estimates